In our “HOT” stock article today, Michael Gable, MD of Fairmont Equities, says Boss Energy (BOE) is a stock he likes because over the next several years the amount of uranium supply coming online isn’t enough to meet current demand.
Raymond Chan, Head of Asian Desk at Morgans, is again a fan of Resmed (RMD). In our “HOT STOCK” column today, Raymond goes through the reasons why he continues to believe RMD is an ADD to an investor’s portfolio.
In our “HOT” stock article today, Michael Gable, MD of Fairmont Equities, explains why he expects Pinnacle Investment (PNI) to rally higher from here.
In our “HOT” stock article today, Michael Gable, MD of Fairmont Equities, says that with China banning the exports of rare earths to the US, Lynas Rare Earths (LYC) is a buy again.
In our “HOT STOCK” column today, Raymond Chan, Head of Asian Desk, gives us a rundown on what tariffs apply to various pharma stocks and which pharma he sees as an ADD to an investor’s portfolio.
In our “HOT” stock article today, Michael Gable, MD of Fairmont Equities, says that for investors still looking to stick with trending stocks, then you can’t go past gold companies, and current levels for Ramelius Resources (RMS) are a buying opportunity.
In our “HOT STOCK” column today, Raymond Chan, Head of Asian Desk, comments on the position of CSL with regards to the impact of the Trump imposed tariffs.
In our “HOT” stock article today, Michael Gable, MD of Fairmont Equities, says that Macquarie Group (MQG) is a buying opportunity right now.
In our “HOT STOCK” column today, Raymond Chan, Head of Asian Desk, explains that Macquarie Group Ltd (MQG) continues to emphasise its strong long-term structural growth potential.
In our “HOT” stock article today, Michael Gable, MD of Fairmont Equities, explains that it appears as though Telix Pharmaceuticals (TLX) is back in the uptrend and current prices are a buying opportunity.
You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.